InsideOut Institute’s statement on GLP-1 Agonists

InsideOut Institute has recently launched a survey on GLP-1 Agonists. This statement outlines the views of InsideOut Institute on the subject.

 

As new medications emerge which may have implications for individuals with eating disorders, we seek to increase our understanding of how they work, and their potential risks and benefits through research. Understanding how weight loss medications like GLP-1 agonists affect different people may provide novel insights into key drivers of appetite and eating behaviours.

 

InsideOut acknowledges our collective understanding of these medications is limited. Further research is needed to verify the effects of taking these relatively new medications.

 

We support the need for a dedicated research effort to ensure researchers, clinicians and the wider workforce are well informed about the risks and possible benefits of GLP-1 agonists to appropriately guide and inform the care of people with eating disorders.

 

InsideOut has no relationship and receives no funding from any pharmaceutical company that develops GLP-1 agonists.